The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosisEnrico Costa, Marco Cipolli, Silvia Girotti et al.|Orphanet Journal of Rare Diseases|2022Cited by 51
Traits, trends and hits of orphan drug designations in cystic fibrosisEnrico Costa, Hubert G. M. Leufkens, Marco Cipolli et al.|Journal of Cystic Fibrosis|2023Cited by 6
Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European UnionEnrico Costa, Hubert G. M. Leufkens, Silvia Girotti et al.|Journal of Cystic Fibrosis|2024Cited by 6